文献速递胸部肿瘤

抗PD-1免疫治疗在BRAF、HER2、MET突变或RET融合晚期NSCLC中的疗效与安全性:GFPC 01-2018

Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018.
PubMed 文献 · J Thorac Oncol · 2020-01-13

该回顾性多中心研究纳入107例携带BRAF、HER2、MET突变或RET融合的晚期NSCLC患者,评估抗PD-1免疫检查点抑制剂的真实世界疗效。全队列中位无进展生存期4.7个月,中位总生存期16.2个月,各分子亚型客观缓解率26%–38%,毒性可控。

要点

  • BRAF、HER2、MET突变或RET融合NSCLC的免疫治疗疗效与未选择人群接近。
  • 各亚型客观缓解率:BRAF-V600 26%、BRAF-non-V600 35%、HER2 27%、MET 36%、RET 38%。
  • PD-L1阳性患者总生存期数值上长于阴性患者,但置信区间宽泛。

核心结论

  • 在真实世界中,ICI对BRAF、HER2、MET突变或RET融合NSCLC的疗效似乎与未选择NSCLC患者接近。
  • 需要针对这些分子亚型患者开展大型前瞻性研究。

研究设计与样本

  • 回顾性、多中心研究,纳入21个中心的107例经ICI治疗的BRAF、HER2、MET突变或RET融合晚期NSCLC患者。
  • 患者平均年龄65.5岁,37%从不吸烟,54%为男性,93%为腺癌。
  • 44例BRAF突变(V600 26例),23例HER2突变,30例MET突变,9例RET融合。
  • 70例已知PD-L1状态,其中34例PD-L1≥1%。
  • ICI治疗前中位治疗线数为1线。

主要发现

  • 全队列中位缓解持续时间15.4个月(95%CI 12.6–NR),中位PFS 4.7个月(95%CI 2.3–7.4),中位OS 16.2个月(95%CI 12.0–24.0)。
  • BRAF-V600、BRAF-non-V600、HER2、MET、RET亚型客观缓解率分别为26%、35%、27%、36%、38%。
  • PD-L1阴性 vs 阳性患者中位PFS分别为3.0个月(95%CI 1.2–NR)和4.3个月(95%CI 2.1–8.5),中位OS分别为11.7个月(95%CI 4.1–NR)和35.8个月(95%CI 9.0–35.2)。
  • 28例(26%)报告毒性,其中11例(10%)≥3级。

临床怎么用

  • 对于携带BRAF、HER2、MET突变或RET融合的晚期NSCLC,ICI可作为治疗选择之一,疗效与未选择人群相近。
  • PD-L1状态可能有助于预测OS获益,但需结合其他临床因素综合判断。
  • 治疗期间需监测免疫相关毒性,≥3级毒性发生率为10%。

局限性

  • 回顾性研究设计,存在选择偏倚和信息偏倚。
  • 样本量较小(107例),部分亚型例数更少(如RET仅9例)。
  • PD-L1状态仅70例已知,存在数据缺失。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Immune-checkpoint inhibitor (ICI) efficacy in patients with NSCLC harboring molecular alterations remains poorly elucidated. This study was undertaken to determine ICI efficacy against BRAF-, HER2-, MET-, and RET-NSCLC in a real-world setting. METHODS: In this retrospective, multicenter study in ICI-treated BRAF-, HER2-, MET- or RET-NSCLCs, we analyzed clinical characteristics and outcomes: ICI-treatment duration, progression-free survival (PFS), objective response rate, duration of response, and overall survival (OS). RESULTS: There were 107 patients with NSCLC (mean age, 65.5 y) included from 21 centers: 37% were never-smokers, 54% were men, and 93% had adenocarcinoma. Among them, 44 had BRAF mutation (V600: 26), 23 had HER2 mutation, 30 had MET mutation, and nine had RET translocation. Programmed cell death ligand 1 (PD-L1) status was known for 70 patients and was greater than or equal to 1% in 34 patients. Before ICI, patients had received a median of one treatment line. Median duration of response, PFS, and OS were 15.4 (95% confidence interval [CI]: 12.6-not reached [NR]) months, 4.7 (95% CI: 2.3-7.4) months, and 16.2 (95% CI: 12.0-24.0) months, respectively, for the entire cohort. The response rates for BRAF-V600, BRAF-non-V600, HER2, MET, and RET-altered NSCLC were 26%, 35%, 27%, 36%, and 38%, respectively. For patients who were PD-L1 negative and those who were PD-L1 positive, PFS was 3.0 (95% CI: 1.2-NR) and 4.3 (95% CI: 2.1-8.5) months, respectively, and OS was 11.7 (95% CI: 4.1-NR) and 35.8 (95% CI: 9.0-35.2) months, respectively. Toxicities were reported in 28 patients (26%), including 11 patients (10%) with a grade greater than or equal to three. CONCLUSIONS: In this real-world setting, ICI efficacy against patients with BRAF-, HER2-, MET-, or RET-NSCLC seemed close to that observed in unselected patients with NSCLC. Large prospective studies on these subsets of patients are needed.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Guisier F, Dubos-Arvis C, Viñas F, et al. Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018. J Thorac Oncol. 2020. PMID: 31945494. doi:10.1016/j.jtho.2019.12.129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。